Key Takeaways Kenvue affirmed its full-year revenue growth projection, the midpoint of which is above analysts' expectations. The Band-Aid owner reported second-quarter revenue that slightly beat consensus estimates. Kenvue shares soared 13% in intraday trading. Kenvue (KVUE) shares surged in intraday trading Tuesday after the company affirmed its full-year guidance that topped analysts' expectations. The Tylenol and Band-Aid parent, formerly the consumer healthcare unit of Johnson & Johnson (JNJ), continue ...